Embryonic Stem Cells

StratifiREY

Liver Cancer

livercancer.png
6th

most common

cancer globally

jolly-roger.png
3rd

leading cause of 

cancer-related death 

worldwide in 2020

group-of-people-in-a-formation.png
>1 Million

individuals are estimated

to be affected by

liver cancer by 2025 

Y90 Radioembolization

Hepatocellular Carcinoma (HCC) is the most common type of liver cancer.

Y90 Radioembolization (RE), also known as transarterial radioembolization (TARE), is one of the treatment options for unresectable HCC. 

Y90 RE involves the injection of glass or resin microspheres containing radioactive yttrium-90 into the liver artery via a catheter

livercancerpatient.png

Microspheres are lodged in the small blood vessels near the tumour, where they release radiation to the tumour.

As the radiation is delivered directly to the tumour, its effects are limited mainly to the tumour while the liver remains relatively unaffected.      

2

1

Challenge

Clinicians are unable to predict if a patient will respond to Y90 RE treatment and patients have to wait 3 to 6 months before knowing whether Y90 RE had worked
 

livercancerpatient.png
radiation.png
user.png
user.png
user.png
user.png
user.png
user.png
user.png
user.png
user.png
user.png

Liver cancer patient

Treatment with Y90 RE

Only 3 out of 10 patients

will respond* to treatment**

*Defined by lack of disease progression at 6 months post-treatment

**Based on preliminary study

dollar (1).png

Unnecessary healthcare expenses and valuable time loss

Solution

 StratifiREY can predict if a patient will respond to Y90 RE to help clinicians make more informed decisions on whether the patient should proceed with Y90 RE or alternative treatments
 

livercancerpatient.png
bloodtube.png

Predicted

responders

radiation.png

Liver cancer patient

Use of StratifiREY Y90 RE Companion Diagnostic Test 

Treatment with Y90 RE

Predicted

non-responders

user.png
user.png
user.png
user.png
user.png
user.png
user.png
dollar.png

7 predicted non-sustained responders referred to alternative treatment such as TACE or immunotherapy 

Avoid unnecessary Y90 RE treatment and patients do not have to wait for 3-6 months to see if Y90 RE works

user.png
user.png
user.png

All 3 predicted responders respond to Y90 RE treatment

How StratifiREY works

Recent research has found that Y90 RE recruits activated white blood cells (WBCs) to the liver, where they kill the tumour cells. This radiation-induced immune response is a possible reason why maximum clinical response is only observed 3 to 6 months after treatment with Y90 RE although the radiation dissipates after 2 weeks. 

 

StratifiREY is an immune-profiling companion diagnostic test that uses a panel of WBC biomarkers to determine a patient's response to Y90 RE.

1

test-tube.png

Collect patient's blood sample and isolate peripheral blood mononuclear cells (PBMC)

2

FC.png

PBMC analysed using flow cytometry 

3

computer.png

Analysis of results using a machine learning prediction model to determine patient's response to Y90 RE 

Benefits

happiness.png

Ease of mind

Patients do not have to wait for 3 to 6 months before knowing whether they have responded to Y90 RE treatment   

coin.png

Cost Savings

Save on unnecessary Y90 RE treatment cost if patient is predicted to be a non-sustained responder

heart(blue).png

More informed decision

Clinicians will have more information to decide which treatment is better suited for the patient  

seo-and-web.png

Assay Accuracy

82% sensitivity and 100% specificity.*

Based on preliminary studies

Enquire on StratifiREY now